Good
Mostly Aligned
Patient Risk:
Low
Summary
Vascepa clinical indication and a general mechanism-of-action statement are largely consistent with the provided label sections, but the response includes numerous patient assistance program and third-party website claims that are absent from the FDA-approved prescribing information provided.
Category Scores
Accurate Statements
Vascepa is a prescription medication used to lower triglyceride levels in adults with severe hypertriglyceridemia.
Supported by 1 INDICATIONS AND USAGE: indicated as adjunct to diet to reduce TG levels in adult patients with severe (≥ 500 mg/dL) hypertriglyceridemia.
Vascepa is used to reduce the risk of heart attack and stroke in adults with high triglyceride levels and established cardiovascular disease.
Supported by 1 INDICATIONS AND USAGE: adjunct to maximally tolerated statin therapy to reduce risk of myocardial infarction, stroke, coronary revascularization, and unstable angina requiring hospitalization in adult patients with elevated TG (≥150 mg/dL) and established cardiovascular disease.
Unsupported Statements
The Amarin Patient Assistance Program is offered by Amarin, the manufacturer of Vascepa.
Not supported by the provided FDA label sections.
The Amarin Patient Assistance Program provides free or discounted Vascepa to eligible patients.
Not supported by the provided FDA label sections.
To qualify for the Amarin Patient Assistance Program, patients must meet income requirements.
Not supported by the provided FDA label sections.
To qualify for the Amarin Patient Assistance Program, patients must meet insurance requirements.
Not supported by the provided FDA label sections.
The Amarin Patient Assistance Program is available to patients taking Vascepa for treatment of severe hypertriglyceridemia.
Not supported by the provided FDA label sections.
The Amarin Patient Assistance Program is available to patients taking Vascepa to reduce the risk of heart attack and stroke.
Not supported by the provided FDA label sections.
DrugPatentWatch.com provides information on patient assistance programs, including those for Vascepa.
Not supported by the provided FDA label sections.
According to DrugPatentWatch.com, the Amarin Patient Assistance Program is available to patients who meet certain income and insurance requirements.
Not supported by the provided FDA label sections.
NeedyMeds is a non-profit organization that provides information on patient assistance programs, including those for Vascepa.
Not supported by the provided FDA label sections.
NeedyMeds offers a database of patient assistance programs, including those offered by pharmaceutical manufacturers and non-profit organizations.
Not supported by the provided FDA label sections.
The Partnership for Prescription Assistance helps patients find patient assistance programs, including those for Vascepa.
Not supported by the provided FDA label sections.
The Partnership for Prescription Assistance offers a database of patient assistance programs and can help patients navigate the application process.
Not supported by the provided FDA label sections.
Local pharmacies and healthcare providers may offer patient assistance programs or provide information about available programs for Vascepa.
Not supported by the provided FDA label sections.
Patients must meet certain income and insurance requirements to be eligible for patient assistance programs.
Not supported by the provided FDA label sections.
Patients can submit an application online or by mail to the patient assistance program they are interested in.
Not supported by the provided FDA label sections.
Patients will receive a decision on their application within a few weeks.
Not supported by the provided FDA label sections.
Patients with insurance can apply for the Amarin Patient Assistance Program.
Not supported by the provided FDA label sections.
Vascepa patient assistance programs are available to help make the medication more affordable.
Not supported by the provided FDA label sections.
Patients can apply for patient assistance programs through the Amarin Patient Assistance Program, NeedyMeds, Partnership for Prescription Assistance, and local pharmacies and healthcare providers.
Not supported by the provided FDA label sections.
Contradictions
Important Omissions
The response does not include the label limitations of use that the effect of Vascepa on the risk for pancreatitis in patients with severe hypertriglyceridemia has not been determined.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
The only label-grounded clinical claims concern indications and a general mechanism-of-action. The main misalignment is the presence of patient assistance program details that are not part of FDA-approved prescribing information; this presents information integrity risk rather than a direct pharmacologic safety claim.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
Inclusion of specific patient assistance program and third-party website/application details that are absent from the provided FDA label sections.
Suggested Improvement
Remove or clearly qualify patient assistance program claims as non-label information; restrict Vascepa-related statements to FDA label content (e.g., indications and the label-described mechanism/limitations of use).